C12N 2760/18552
Relating to complementing cells and packaging systems for producing virus or viral
Official title: relating to complementing cells and packaging systems for producing virus or viral particles
C12N2760/18552 (Relating to complementing cells and packaging systems for producing virus or viral) appears on 7 US grants and 10 published applications in this corpus.
Search patents in C12N- Granted patents
- 7
- Published applications
- 10
- Assignees
- 8
- Inventors
- 26
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 2 |
| 2011 | 0 | 0 |
| 2012 | 0 | 1 |
| 2013 | 1 | 0 |
| 2014 | 0 | 0 |
| 2015 | 1 | 1 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 1 | 1 |
| 2019 | 1 | 1 |
| 2020 | 1 | 0 |
| 2021 | 1 | 0 |
| 2022 | 0 | 0 |
| 2023 | 0 | 0 |
| 2024 | 0 | 1 |
| 2025 | 0 | 2 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Cell culture process for producing RSV F protein15 Sep 2026US 12,734,231 B2Pfizer Inc.
- Respiratory syncytial virus with a genomic deficiency complemented in trans6 Apr 2021US 10,967,014 B2De Staat der Nederlanden, vert. door de minister van VWS
- Respiratory syncytial virus expression vectors21 Apr 2020US 10,626,378 B2Children's Healthcare of Atlanta, Inc.
- Respiratory syncytial virus expression vectors12 Mar 2019US 10,227,569 B2Children's Healthcare of Atlanta, Inc.
- Respiratory syncytial virus with a genomic deficiency complemented in trans13 Feb 2018US 9,889,168 B2De Staat der Nederlanden, vert. door de minister van VWS
- Plasmid dna purification methods1 May 2025US 2025/0137024 A1Glaxosmithkline Biologicals SA
- Modified vero cells and methods of using the same for virus production10 Apr 2025US 2025/0115881 A1Sanofi Pasteur Limited
- Cell culture process for producing RSV F protein18 Jan 2024US 2024/0016915 A1Pfizer Inc.
- Respiratory Syncytial Virus Expression Vectors6 Jun 2019US 2019/0169579 A1Children's Healthcare of Atlanta, Inc.
- Respiratory syncytial virus with a genomic deficiency complemented in trans26 Jul 2018US 2018/0207211 A1De Staat der Nederlanden, vert. door de minister van VWS
Most cited
By later US patents
- Respiratory syncytial virus with a genomic deficiency complemented in trans7US 9,107,939 B2De Staat der Nederlanden, vert. door de minister van VWS · 2015
- Polyvalent chimeric rubella virus-based vaccines4US 8,460,680 B2National Health Research Institutes · 2013
- Respiratory syncytial virus expression vectors3US 10,227,569 B2Children's Healthcare of Atlanta, Inc. · 2019